Andrew J. Cowan, MD, is an associate professor in the Clinical Research Division of Fred Hutchinson Cancer Center in Seattle. As I’m sure many of my multiple myeloma (MM) colleagues in the U.S. can agree, the recent approvals of ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel) for patients with relapsed MM who have received more than one line and two lines of therapy, respectively, have been exciting but have also led to many conversations about how to prioritize patients. At